Post on 16-Jul-2015
info@BrainBackups.com
Our Name - Brain Backups
High-Resolution Brain Imaging Platform
Nondestructive, noninvasive, whole brain in vivo imaging at the connectome level
Current methods for whole brain imaging
● Current methods of whole brain in vivo imaging do not provide adequate resolution.
● Methods providing adequate resolution have incomplete coverage, or require
destructive slicing of the brain.
First Target: An Early & Accurate Parkinson’s Disease Diagnostic
info@BrainBackups.com
The Solution - AptaMark
Accurate & Objective
Dopamine D2R test
AptaMark will be the first contrast agent with a single
cell resolution, allowing neurodegeneration in the
substantia nigra and other relevant areas can be tracked
objectively.
• First Objective Diagnostic for PD
• Enables early detection
• Tracks degradation directly at source
• Differentiates amongst PD subtypes
• Non destructive/non invasive
• 1 micron resolution
info@BrainBackups.com
● 34 drugs in development
● Aging population
● $26B in US Healthcare Costs
● $3B in PD specific treatment “Large potential market for neurotechnology”
- NeuroTech Business Report
The Opportunity
PD diagnosis and mid-treatment imaging demand will
continue to grow.
info@BrainBackups.com
Competitive Analysis
Cost Accuracy Early
Detection
Objectivity Resolution
Doctors Low ~76% Clinical No N/A
Movement
Software
$100 Low Clinical Yes N/A
CT $700 Moderate Clinical No 1mm
MRI $1,200 ~85% Clinical No 1mm
DaTscan $5,000 ~84% Clinical No 1mm
AptaMark $2,800 Aim >90% Preclinical Yes 1µm
info@BrainBackups.com
The Competitors
New contrast agents are being developed every year.
All lack the specificity of AptaMark and many rely on expensive small molecule chemistry &
approvals process and often less precise methods.
DaTscan is a SPECT iodine-123 contrast agent that
images dopamine transporter and allows clinicians to
distinguish essential tremor from PD.
AptaMark permits imaging at 1 micron resolution,
100X better than MRI; offers specificity to subtypes
of dopamine receptors; uses same GE imaging
hardware provides better diagnosis.
info@BrainBackups.com
Revenue Projections
Assuming a 5% market share in Y4, we can reasonably expect close to
$4M per year in initial diagnostic revenue.
If AptaMark is used in treatment management, revenue growth becomes exponential.
40,000 out of 1.5M total patients tested twice a year will result in $100M of revenue.
Market Share RevenueCost per Test
As costs decrease with scale, EBITA will grow from
11% to more than 48% as quantity grows past 1000.
info@BrainBackups.com
Potential Partnerships
From MRI to aptamers, a lot of companies work with relevant
technology. We are continuing an active outreach process to
engage researchers and clinicians alike with our technology.
info@BrainBackups.com
The Team
Mihai Dinulescu
Russell Hanson Jason Fuller
Robert Cunningham Webster Heffern
info@BrainBackups.com
...to demonstrate Parkinson’s can be imaged at the source.
● $2.5M for further optimization & research deployment
● Potentially positive ROI from research revenue alone
● $30M+ for Phase I & Phase II toxicology trials
● Exit after proven safety & efficacy
● Clinical trials performed through partnerships
What we are asking for...
info@BrainBackups.com
30,000 Validation and Optimization 1.2%
20,000 Scale up batches 0.8%
50,000 At scale batches 2%
400,000 Real estate: laboratory & office space 16%
250,000 Main laboratory equipment 10%
500,000 In vivo validation FDA 510K 20%
100,000 Licensing to established vendors 4%
1,100,000 Personnel and marketing 44%
50,000 To be budgeted and incidentals 2%
Total:
2,500,000 100%
Appendix: Financial I - $2.5M Series A Breakdown
info@BrainBackups.com
Appendix: Financial II - Research Revenue
Core product is a recurring cost consumable ● Initial product cost*: $1,300/test
● Scale product costA: $550/test
● Cost to consumer: $2,800/test
● Break-even point T: ~1,200 tests
● Assuming an MRI cost of ~$1,000, AptaMark is competitive with DaTscan
for diagnostic and treatment management imaging
● Even with 80% production profit margin, AptaMark remains 100x more
rentable than current destructive research methods
A Cost estimates are for total cost of production, manufacturing, and overhead at appropriate stage
* Assumes 200+ test batches T At scale cost, associated profit margin, and 2.5M Series A
info@BrainBackups.com
Appendix: Financial III - Ancillary Markets
Research Products
● Alzheimer’s
● Autism
● Huntington’s
● Schizophrenia
● Additional research
● Obsessive Compulsive Disorder
● Etc...
info@BrainBackups.com
Appendix: Science I - About Aptamers
Advantages of Using Aptamers
● Very small, very precise ~ 1 micron
● Chemically synthesized, no bioreactors
● Easy to ship, safe to handle
● Cross blood brain barrier
● Don’t trigger the neurons they bind to
● Safely cleared
info@BrainBackups.com
Appendix: Science II - Technology Details
Gold nanoparticle with attached D2-specific ligand
Rat knee imaged at 3 microns (0.003mm voxel)
Nanoparticle uniformity validation using dynamic light
scattering